Work

The development and application of a prognosis prediction model for children with chronic hepatitis B

Year: 2020

Type: article

Abstract: IRB#18EC003; registered to jRCT (#jRCTs061180100).NASVAC was emulsified in carboxyl vinyl polymer to increase the viscosity, then administrated for 10 times, once in every 2 weeks, by a special device designed for durable existence of NASVAC in nasal mucosa.Data were analyzed at 6 months after end of treatment (EOT).Results: Twenty nine HBV patients under NAs treatment (NA group: age: 49-66 years, ALT: 16-28 U/L, HBsAg: 93-1942 IU/mL) and forty two chronic HBV infection without hepatitis (w/o NA group: age: 44-64 years, ALT: 16-29 U/L, HBsAg: 311-3706 IU/mL) were enrolled.75% of NA and 74.3% of w/o NA displayed HBsAg reduction, the mean HBsAg reduction was 16.7% in NA and 18.3% in w/o NA at 6 months after EOT.37.9% in NA and 58.5% in w/o NA developed anti-HBs.HBV-DNA reduction was observed in 68.2% of w/o NA and 3 patients showed sustained HBV-DNA negativity. 4 patients, two in NA and two in w/o NA, achieved functional cure.Conclusion: NASVAC induced anti-HBs, and reduced HBsAg in CHB with NAs and chronic HBV infection.Overall 4 patients achieved functional cure by NASVAC.NASVAC could be a novel immune therapy for achieving functional cure in HBV infected patients.

Source: Journal of Hepatology

DOI: 10.1016/s0168-8278(20)32213-3